Review

Author for correspondence:
Patrick M. Fisher
e-mail: patrick.fisher@nru.dk

Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans

Patrick M. Fisher[1,2] and Ahmad R. Hariri[3,4]

[1]Center for Integrated Molecular Brain Imaging, and [2]Neurobiology Research Unit, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark
[3]Laboratory of NeuroGenetics, Department of Psychology and Neuroscience, and [4]Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA

A corticolimbic circuit including the amygdala and medial prefrontal cortex (mPFC) plays an important role in regulating sensitivity to threat, which is heightened in mood and anxiety disorders. Serotonin is a potent neuromodulator of this circuit; however, specific serotonergic mechanisms mediating these effects are not fully understood. Recent studies have evaluated molecular mechanisms mediating the effects of serotonin signalling on corticolimbic circuit function using a multi-modal neuroimaging strategy incorporating positron emission tomography and blood oxygen level-dependent functional magnetic resonance imaging. This multi-modal neuroimaging strategy can be integrated with additional techniques including imaging genetics and pharmacological challenge paradigms to more clearly understand how serotonin signalling modulates neural pathways underlying sensitivity to threat. Integrating these methodological approaches offers novel opportunities to identify mechanisms through which serotonin signalling contributes to differences in brain function and behaviour, which in turn can illuminate factors that confer risk for illness and inform the development of more effective treatment strategies.

1. Introduction

Major depressive disorder (MDD) is an affective disorder characterized by depressed mood, increased feelings of sadness and diminished interest or pleasure in general activities [1]. Within a twelve-month period, approximately 6–7% of the population experiences a depressive episode [2]. Thus, MDD represents a prevalent disorder with substantial burdens on public health that contribute to emotional and financial pressures on affected individuals, their families and society as a whole [3]. A study evaluating treatment efficacy in a large population reported less than 50 per cent response rate and even lower rates of remission, indicating that treatment efficacy can be improved dramatically [4]. As such, a clearer understanding of factors that contribute to risk for and the pathophysiology of MDD is critical for (i) identifying at-risk populations, (ii) developing novel therapeutics targeting specific molecular mechanisms, and (iii) identifying biomarkers predictive of treatment response. Though the precise mechanisms that precipitate a depressive state are not fully understood, trait-like behaviours such as anxiety and neuroticism have been identified as risk factors for MDD and other affective disorders [5–8]. Thus, evaluating neurobiological mechanisms related to these aspects of personality may in turn be informative of individual differences in risk for clinical illness [9].

2. A threat-related corticolimbic circuit

The amygdala is a subcortical brain structure integral for identifying novel and biologically relevant stimuli within the environment. The amygdala exhibits a particular sensitivity for threat-related cues (e.g. facial expressions of fear and

anger) and plays an important role in learning associations between stimuli and events that predict threat [10–13]. Numerous neuroimaging studies in humans, most commonly using blood oxygen level-dependent functional magnetic resonance imaging (BOLD fMRI), have identified a positive association between threat-related amygdala reactivity and trait anxiety or related constructs [14–17]. A distributed corticolimbic circuit including the amygdala and prefrontal cortical regions, namely medial prefrontal cortex (mPFC) and anterior cingulate cortex (Brodmann areas: 24/25/32), plays a key role in multiple facets of emotional behaviour; most notably in the generation, regulation and expression of behavioural and physiological arousal [18–24]. Effective communication within this corticolimbic circuit is thought to play a critical role in integrating salient information and generating adaptive responses to environmental challenges [20]. Neuroimaging studies have also identified an association between functional and structural indices of this corticolimbic circuit and personality measures associated with anxiety [25–30]. Similarly, neuroimaging studies in depressed patients have identified alterations in both threat-related amygdala reactivity and broader corticolimbic circuit function [18,31–34]. Linking discrete molecular mechanisms with individual differences in threat-related corticolimbic circuit function would allow for a more detailed understanding of how brain chemistry contributes to circuit function and disease liability.

3. Serotonin signalling and the corticolimbic response to threat

Serotonin (5-hydroxytryptamine, 5-HT) is a neuromodulator with significant effects on emotional behaviour, including anxiety and sensitivity to threat [35–37]. Serotonergic neurons, derived primarily from the dorsal and median raphe nuclei, innervate this corticolimbic circuit [38]. Direct modulation of this circuitry may underlie the effects of serotonin on emotional behaviour [39–41]. Consistent with its role in regulating mood, a convergence of evidence suggests that serotonin may play a role in the pathophysiology of depression. Human neuroimaging studies have provided novel insight into how serotonin signalling modulates underlying corticolimbic circuit function and individual variability in personality traits such as anxiety, which are related to risk for depression and other affective disorders. Most notably, imaging genetics has repeatedly identified links between threat-related corticolimbic circuit function and genetic variants, which putatively impact serotonin signalling [17,25,42–46]. Pharmacological challenge paradigms have identified an effect of selective serotonin reuptake inhibitors (SSRIs) on corticolimbic circuit function both in healthy controls and depressed patients, suggesting that antidepressant treatment response may in part depend on modulation of this corticolimbic circuit [47–52].

The serotonin system consists of multiple receptor classes (e.g. 5-HT$_1$, 5-HT$_2$) and subtypes within these classes (e.g. 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{1D}$,). Thus, an important aspect in understanding how serotonin contributes to inter-individual variability in personality and related risk for MDD, and other affective disorders, is identifying molecular mechanisms (i.e. receptor pathways) mediating the effects of serotonin signalling on threat-related corticolimbic circuit function. Positron emission tomography (PET) can be used to quantify the availability of a particular molecular

substrate, including receptors, in humans. Such neuroreceptor PET offers a unique opportunity to model capacity for receptor-related function, *in vivo*. Thus, a PET–fMRI multi-modal neuroimaging strategy evaluating the association between threat-related brain function, assessed using BOLD fMRI, and serotonin receptor binding, assessed using PET, can be used to evaluate the effects of serotonin receptor pathways on brain function, behaviour and psychopathology.

4. Multi-modal neuroimaging studies

(a) 5-HT$_{1A}$ autoreceptor

The inhibitory 5-HT$_{1A}$ receptor is expressed as both an auto-receptor and post-synaptic receptor [53,54]. Through negative feedback inhibition on serotonergic neurons, the 5-HT$_{1A}$ somatodendritic autoreceptor plays a critical role in regulating 5-HT release at downstream targets [55]. Alterations in 5-HT$_{1A}$ availability have been previously associated with depression, and therapeutic efficacy of many antidepressants may depend on modulation of 5-HT$_{1A}$ autoreceptor signalling [56–58]. Using a PET–fMRI multi-modal neuroimaging approach, we examined the association between individual variability in 5-HT$_{1A}$ autoreceptor binding, assessed with [^{11}C]WAY100635 PET, and threat-related amygdala reactivity, assessed with BOLD fMRI. By evaluating the association between 5-HT$_{1A}$ autoreceptor binding and threat-related amygdala reactivity within a single cohort, this novel multi-modal neuroimaging strategy offered the opportunity to identify specific molecular mechanisms through which serotonin signalling may contribute to inter-individual variability in threat-related amygdala reactivity.

Within a cohort of 20 individuals we found that 5-HT$_{1A}$ autoreceptor binding was significantly inversely correlated with threat-related amygdala reactivity [59]. Remarkably, 30–44% of the variability in threat-related amygdala reactivity was predicted by variability in 5-HT$_{1A}$ binding within the dorsal raphe, suggesting that a greater capacity to regulate serotonin release (i.e. greater 5-HT$_{1A}$ autoreceptor binding) was associated with reduced amygdala response to threat-related stimuli. These findings provide evidence for a molecular mechanism through which serotonin signalling modulates the brain's response to emotionally salient, threat-related stimuli. Intriguingly, our findings link a molecular mechanism (i.e. 5-HT$_{1A}$ autoreceptors) and an aspect of brain function (i.e. amygdala sensitivity to threat), which independently has been identified in previous studies as altered in depressed cohorts [50,58]. Considering studies in animal models indicating that the 5-HT$_{1A}$ autoreceptor may be a critical mechanism through which SSRIs exert their antidepressant effect, our findings suggest amygdala sensitivity to threat may reflect a neural pathway contributing to antidepressant treatment response.

(b) Serotonin transporter

Reuptake of serotonin via the serotonin transporter represents the primary mechanism for active clearance of extracellular serotonin following release [60]. In a multi-modal neuroimaging study using the same threat-related faces matching BOLD fMRI paradigm as was used in our 5-HT$_{1A}$ autoreceptor study, Rhodes *et al.* [61] evaluated the association between 5-HTT binding in the amygdala, assessed with [^{11}C]DASB PET, and threat-related amygdala reactivity. The authors

found that amygdala 5-HTT binding was significantly inversely associated with threat-related amygdala reactivity, with up to 40 per cent of the variability in threat-related amygdala reactivity predicted by 5-HTT binding levels. These findings suggest that inter-individual variability in the capacity to regulate serotonin signalling locally within the amygdala via serotonin reuptake is related to the response of the amygdala to threat. A recent study reported an inverse correlation between midbrain (i.e. raphe) 5-HTT binding and threat-related amygdala reactivity [62]. Although no association was then observed between amygdala 5-HTT binding and amygdala reactivity, this finding provides additional evidence for a link between the capacity to regulate 5-HT signalling and threat-related amygdala reactivity.

Taken together with our findings, these studies provide strong support for serotonin as a key modulator of threat-related amygdala reactivity. Perhaps more interestingly, these findings indicate that regulation via autoreceptor feedback and reuptake represents a critical molecular mechanism through which serotonin signalling modulates neural sensitivity to threat. Thus, a compromised capacity to regulate serotonin signalling, resulting in a diminished capacity to regulate amygdala reactivity to threat, may in turn contribute to heightened risk for affective disorders such as depression. These findings support the capacity for this multi-modal neuroimaging framework to link serotonin signalling mechanisms with brain function, and more effectively model how molecular mechanisms may contribute to variability in behaviour and psychopathology.

(c) Prefrontal 5-HT$_{2A}$ receptor

Within the prefrontal cortex, the excitatory 5-HT$_{2A}$ receptor is predominantly localized on glutamatergic neurons [63–66]. More specifically, the 5-HT$_{2A}$ receptor is localized to proximal portions of the apical dendrite, representing a 'hot spot' of 5-HT$_{2A}$ receptor localization coincident with relatively dense 5-HT innervation [63,67]. Previous studies in animal models and humans implicate serotonin signalling and the 5-HT$_{2A}$ receptor in modulating prefrontal function in the context of fear- or anxiety-related behaviours and depression [39, 68–71]. Using this multi-modal neuroimaging strategy in a cohort of 35 healthy individuals, we evaluated the association between mPFC 5-HT$_{2A}$ binding, assessed with [^{18}F]altanserin PET, and threat-related corticolimbic circuit function [72]. Based on its localization, we hypothesized that 5-HT$_{2A}$ binding within mPFC would facilitate this prefrontal regulatory circuitry and be negatively correlated with threat-related amygdala reactivity. Consistent with this model, we found that 5-HT$_{2A}$ binding was significantly inversely correlated with threat-related amygdala reactivity, such that 25–37% of the variability in amygdala reactivity was explained by mPFC 5-HT$_{2A}$ binding. Additionally, we observed that mPFC 5-HT$_{2A}$ binding was positively correlated with the magnitude of amygdala habituation over time. Finally, we observed that 5-HT$_{2A}$ binding was positively correlated with functional connectivity between the amygdala and mPFC. Studies in both animal models and humans suggest that habituation of the amygdala response to threat is likely dependent upon prefrontal regulation [28,30,73]. Thus, our findings that amygdala habituation and mPFC–amygdala functional connectivity were correlated with mPFC 5-HT$_{2A}$ binding suggests that these receptors are an important molecular

mechanism mediating the effects of serotonin signalling on threat-related corticolimbic circuit function.

(d) Interaction between prefrontal 5-HT$_{1A}$ and 5-HT$_{2A}$ receptors

In addition to the 5-HT$_{2A}$ receptor, the post-synaptic 5-HT$_{1A}$ receptor is also localized to glutamatergic neurons within prefrontal cortex [74–76]. Intriguingly, the 5-HT$_{1A}$ and 5-HT$_{2A}$ receptors appear to be highly co-localized, with both receptors situated proximal to the cell body and thus potential mediators of serotonin signalling on glutamatergic neuronal excitability [75]. Based on this co-localization, the inhibitory 5-HT$_{1A}$ receptor appears to be localized to moderate or 'gate' the capacity of the excitatory 5-HT$_{2A}$ receptor to facilitate regulation of threat-related amygdala reactivity, as was observed in the previously described study. More specifically, this co-localization suggests that the inverse correlation between 5-HT$_{2A}$ binding and threat-related amygdala reactivity should be most pronounced in the context of low 5-HT$_{1A}$ binding, reflecting a reduced capacity for 5-HT$_{1A}$ receptors to gate the negative effect of mPFC 5-HT$_{2A}$ binding on threat-related amygdala reactivity.

Within a cohort of 39 healthy volunteers, we determined the association between threat-related amygdala reactivity and the interaction between 5-HT$_{1A}$ and 5-HT$_{2A}$ binding, assessed with [^{11}C]WAY100635 and [^{18}F]altanserin PET, respectively [77]. Consistent with the co-localization of these receptors, we found that 5-HT$_{1A}$ binding significantly moderated the negative association between 5-HT$_{2A}$ binding and threat-related amygdala reactivity, such that mPFC 5-HT$_{2A}$ binding was significantly inversely correlated with amygdala reactivity, but only when mPFC 5-HT$_{1A}$ binding was relatively low. These findings indicate that molecular interactions between mPFC 5-HT$_{1A}$ and 5-HT$_{2A}$ receptors may play an important role in mediating the effects of serotonin signalling on threat-related corticolimbic circuit function. Interestingly, they suggest that acquiring multiple neuroreceptor PET scans within a PET–fMRI framework can be used to evaluate the impact of interacting receptor mechanisms on brain function.

5. Future directions

The studies presented here highlight how a multi-modal neuroimaging strategy using BOLD fMRI and PET can inform our understanding of serotonergic mechanisms that contribute to individual variability in threat-related corticolimbic circuit function. Together with studies implicating an association between corticolimbic circuit function, anxious traits and psychopathology, findings from these multi-modal neuroimaging studies implicate specific molecular mechanisms in mediating the effects of serotonin signalling on brain function, personality and risk for depression. As mentioned previously, however, serotonin signalling is mediated through a complex system with multiple receptor subtypes [78]. Additional serotonin receptors including 5-HT$_{1B}$, 5-HT$_{2C}$, 5-HT$_4$ and 5-HT$_7$ have been implicated in the function of this corticolimbic circuit as well as anxiety- and depression-related behaviours [40,41,78,79]. Future studies evaluating the impact of these additional receptors on brain function will provide further opportunities to

4

effectively model the impact of serotonin signalling on sensitivity to threat through specific molecular pathways.

6. Integration with other neuroimaging approaches

Advancing our understanding of how genetic and molecular mechanisms shape underlying neural circuits that give rise to complex behaviours and confer risk for illness is critically dependent upon effectively integrating complimentary methodological approaches.

(a) Limitations

Even though this multi-modal neuroimaging strategy represents a powerful approach for evaluating how molecular mechanisms modulate underlying neural circuitry and related behaviours, it has its limitations. Neuroreceptor PET is not a direct measure of receptor function, but rather a measure related to quantity of receptors available for binding to the radioligand. The impact of inactive or internalized receptors on radioligand binding is difficult to quantify and likely varies between receptor systems and radioligands. Exposure to radioactivity and the invasiveness of intravenous or arterial sampling creates additional limitations. Currently, there is no radioligand that has been fully validated in humans to measure endogenous serotonin release. This limits the features of the serotonin system that can be measured in the context of PET. fMRI is an indirect measure of brain function that is based on signal relative to a baseline or control task. Changes in fMRI signal do not directly reflect neural activity and may more closely correspond to changes in local field potential, a signal which is thought to reflect incoming neural signalling [80]. Age-related changes have been reported for many PET radioligands and fMRI paradigms. Collecting the imaging measures within close temporal proximity to one another is important for avoiding potential age-related confounds. Correlations between neuroreceptor PET binding and fMRI brain function must be interpreted as such. Associations between these measures should be evaluated cautiously and paired with strong evidence supporting circuit dynamics. Despite these shortcomings, these two methodologies represent the most effective methods currently available for assaying brain chemistry and brain function. The use of well-documented fMRI paradigms that have been applied across multiple cohorts and repeatedly linked to relevant aspects of personality and behaviour, and well-validated PET radioligands benefit the application of this technique because identified associations can be considered in the context of a broader literature.

(b) Imaging genetics

Over the past decade, imaging genetics has become a commonly used approach for evaluating the impact of common genetic variants on underlying brain function, personality and risk for illness [9,81]. As genes play a fundamental role in our biology, genetic variation plays a critical role in biological sources of individual variability. Developing our understanding of how genetic polymorphisms map onto neurobiological mechanisms benefits our capacity to leverage genetic information to model aspects of underlying brain chemistry and brain function. Imaging genetics with BOLD fMRI has provided substantial insight into how polymorphisms within serotonin-related genes (e.g.

5-HTTLPR) predict inter-individual variability in threat-related corticolimbic circuit function and other neural pathways related to risk for illness [36]. Molecular mechanisms mediating these associations, however, are often based on putative effects described using *in vitro* models, which are susceptible to being too narrowly focused on specific molecular processes. Imaging genetics with neuroreceptor PET, however, offers a possible compliment through the capacity to link common genetic polymorphisms with variation in serotonin receptor binding *in vivo* [82]. For example, although the 5-HTTLPR putatively affects the expression of 5-HTT, it has been associated with alterations in $5-HT_{1A}$ binding *in vivo*, suggesting its effects may extend to additional serotonin signalling mechanisms [83].

Future studies integrating PET–fMRI multi-modal neuroimaging and imaging genetics through sophisticated statistical modelling techniques, such as structural equation modelling or mediation analysis, may provide novel insight into serotonergic mechanisms mediating the effects of genetic variation on threat-related corticolimbic circuit function. For example, 5-HTTLPR short allele carriers show heightened threat-related amygdala reactivity and decreased $5-HT_{1A}$ receptor binding relative to LL individuals [46,83]. Taken together with our observation that $5-HT_{1A}$ autoreceptor binding is inversely correlated with threat-related amygdala reactivity, differences in $5-HT_{1A}$ autoreceptor levels may be an important molecular mechanism mediating 5-HTTLPR effects on threat-related amygdala reactivity. Alternatively, common polymorphisms (e.g. 5-HTTLPR) can be used to model differences in serotonin signalling and associations between specific serotonin receptor binding and brain function can be evaluated against this genetic background. For example, a bias towards greater prefrontal drive and reduced amygdala reactivity via mPFC $5-HT_{2A}$ receptors would be predicted in individuals possessing genetic variants associated with increased 5-HT neurotransmission (e.g. 5-HTTLPR short allele carriers). Leveraging genetic information and imaging approaches through integrated multi-modal neuroimaging strategies such as PET–fMRI are crucial for further developing models of how serotonergic mechanisms may confer risk for depression through effects on underlying neural circuitry. In the case of treatment, such information can be used to apply models of underlying brain chemistry and brain function based on genetic variants, which may benefit the stratification of clinical subgroups according to how likely they are to benefit from particular treatments. Identifying specific receptor mechanisms that modulate relevant brain function would also benefit the development of novel therapeutic targets.

(c) Pharmacological challenge paradigms

Pharmacological challenge paradigms in the context of functional neuroimaging (i.e. pharmaco-fMRI) can be an effective methodological approach for evaluating biological mechanisms and neural circuits underlying behaviour, psychopathology and treatment response. Pharmaco-fMRI paradigms can be used to determine the impact of treatment strategies (e.g. antidepressant treatment) on specific neural circuits, which may mediate antidepressant treatment response. Recent studies have evaluated the impact of SSRI exposure on threat-related amygdala reactivity in healthy cohorts. Interestingly, Bigos *et al.* [48] found that threat-related amygdala reactivity increased following acute intravenous citalopram administration, whereas Harmer *et al.* [49] found that threat-related amygdala

reactivity decreased following a 7-day oral administration protocol in healthy adults. These seemingly opposing findings may in fact depend on time-dependent effects of SSRI exposure on brain function, reflecting the temporal dynamics of SSRI treatment on the serotonin system observed in animal models and thought to underlie the behavioural response to treatment [35,84].

Future studies incorporating pharmacological challenge of specific serotonin receptors or reuptake blockade within a multi-modal neuroimaging framework would provide more direct evidence implicating specific receptor mechanisms in mediating the effects of serotonin signalling on corticolimbic circuit function. For example, experimentally increasing 5-HT neurotransmission (via pharmacologic challenge with a selective serotonin reuptake inhibitor) may lead to an increase in volume transmission and bias serotonin signalling towards $5-HT_{2A}$ receptors, resulting in greater prefrontal drive and subsequently diminished threat-related amygdala reactivity. Additionally, threat-related amygdala reactivity has been previously associated with 5-HTT binding, the primary target of SSRIs [61]. Individuals with higher 5-HTT binding may be more sensitive to disruption of 5-HTT function via SSRI exposure, and thus likely to exhibit a more pronounced sensitivity to SSRIs in the form of greater change in threat-related amygdala reactivity.

(d) Additional neuroimaging methodologies

The current review has focused on the benefits of PET–fMRI multi-modal neuroimaging, however, the general point holds that complementary neuroimaging modalities collected within a single cohort offer a unique opportunity to evaluate how specific molecular mechanisms affect underlying neural circuitry, which cannot be determined through the use of a single neuroimaging technique. A wealth of neuroimaging studies in humans, primarily via imaging genetics and pharmacological challenge paradigms, have implicated serotonin signalling in modulating the neural pathways underlying threat-related behaviour, which is associated with risk for depression. However, as was mentioned previously, the serotonin receptor family and the signalling mechanisms it affects is large and complex. Thus, a nuanced understanding of how these receptors interact and mediate specific aspects of serotonin signalling is critical for more completely understanding the role of serotonin in the pathophysiology of affective disorders including depression. For example, serotonin is known to be a neutrophic factor. Beyond linking molecular mechanisms with functional aspects of neural circuits, study designs evaluating the association between neuroreceptor PET, or perhaps single-photon emission tomography (SPECT), and structural measures (e.g. voxel-based morphometry or diffusion tensor imaging) would provide additional insight into how serotonergic mechanisms might be related to structural characteristics of this corticolimbic circuit [29,62].

(e) Translational perspective

The foundation for interpreting findings from a PET–fMRI multi-modal neuroimaging strategy is an understanding of how serotonergic mechanisms affect similar neural circuits within animal models. Animal models and related studies are critical for the ability to place in context findings from related neuroimaging studies. To gain a more complete understanding of how serotonergic mechanisms modulate underlying neural circuits, translational animal models are ideally situated to evaluate the effect of individual molecular signalling pathways on neural activity and behaviour more directly than neuroimaging paradigms. For example, one of the multi-modal neuroimaging studies described here identified an inverse association between prefrontal $5-HT_{2A}$ binding and threat-related amygdala reactivity that was moderated by prefrontal $5-HT_{1A}$ binding. Future studies in animal models evaluating the effects of prefrontal $5-HT_{2A}$ signalling (via local infusion of a $5-HT_{2A}$ agonist) on excitability of amygdala neurons and whether prefrontal $5-HT_{1A}$ signalling modulates this effect would provide additional support for such a model. This type of model could be further extended to determine whether such signalling mechanisms affect anxiety-related behavioural phenotypes.

(f) Measuring endogenous serotonin release

Identifying PET radiotracers that can effectively model serotonin release in vivo would bolster the usefulness of PET–fMRI multi-modal neuroimaging as a tool for evaluating how serotonin signalling plays a critical role in biasing threat-related corticolimbic circuit function. A PET radiotracer sensitive to in vivo serotonin levels, analogous to the usefulness of $[^{11}C]$raclopride for measuring endogenous dopamine release, is not currently available [85]. However, candidates for measuring endogenous serotonin release with promising results in both animals and humans are currently being evaluated [86–88]. Looking forward, the application of a PET radiotracer for modelling endogenous serotonin release in the context of a dual PET–MRI scanner offers the very exciting opportunity to evaluate the effects of threat-related corticolimbic brain function on serotonin release in real-time, offering still more effective ways of understanding how serotonin signalling modulates underlying neurobiological pathways.

7. Summary

A wealth of evidence implicates serotonin signalling in modulating emotional behaviour through its effects on threat-related corticolimbic circuit function and other neural pathways. The effects of serotonin on these neural pathways potentially underlie its role in the pathophysiology of mood and anxiety disorders such as depression. Neuroimaging in humans represents a valuable tool for evaluating biological sources of inter-individual variability in brain function, behaviour and psychopathology. An emerging multi-modal neuroimaging approach using PET/fMRI offers a unique opportunity to identify molecular mechanisms (e.g. receptor pathways) that mediate the effects of serotonin signalling on underlying neural circuitry. Future studies aimed at integrating this multi-modal neuroimaging strategy with genetic information, pharmacological challenge paradigms and additional imaging modalities are critical for building on our current understanding of how serotonin modulates neurobiological mechanisms that contribute to the emergence of individual differences in complex behavioural traits and related risk for psychopathology. These insights may in turn inform the development of novel therapeutics aimed at specific molecular mechanisms with improved treatment outcomes.

References

1. First MB, Spitzer RL, Gibbon M, Williams JBW. 1996 *Structured clinical interview for DSM-IV axis I disorders: research version, non-patient edition*. New York, NY: New York State Psychiatric Institute, Biometrics Research Department.

2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005 Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch. Gen. Psychiat.* **62**, 617–627. (doi:10.1001/archpsyc.62.6.617)

3. Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER. 1996 Depression in the workplace: an economic perspective. In *Selective serotonin reuptake inhibitors: advances in basic reserach and clinical practice* (eds JP Feighner, WF Boyer), pp. 327–363. New York, NY: John Wiley & Sons Inc.

4. Trivedi MH et al. 2006 Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am. J. Psychiat.* **163**, 28–40. (doi:10.1176/appi.ajp.163.1.28)

5. Kessler RC. 1997 The effects of stressful life events on depression. *Annu. Rev. Psychol.* **48**, 191–214. (doi:10.1146/annurev.psych.48.1.191)

6. Kendler KS, Gatz M, Gardner CO, Pedersen NL. 2006 Personality and major depression: a Swedish longitudinal, population-based twin study. *Arch. Gen. Psychiat.* **63**, 1113–1120. (doi:10.1001/archpsyc.63.10.1113)

7. Kendler KS, Karkowski LM, Prescott CA. 1999 Causal relationship between stressful life events and the onset of major depression. *Am. J. Psychiat.* **156**, 837–841.

8. Kotov R, Gamez W, Schmidt F, Watson D. 2010 Linking 'big' personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. *Psychol. Bull.* **136**, 768–821. (doi:10.1037/a0020327)

9. Hariri AR. 2009 The neurobiology of individual differences in complex behavioral traits. *Annu. Rev. Neurosci.* **32**, 225–247. (doi:10.1146/annurev.neuro.051508.135335)

10. LeDoux JE. 2000 Emotion circuits in the brain. *Annu. Rev. Neurosci.* **23**, 155–184. (doi:10.1146/annurev.neuro.23.1.155)

11. Davis M, Whalen PJ. 2001 The amygdala: vigilance and emotion. *Mol. Psychiat.* **6**, 13–34. (doi:10.1038/sj.mp.4000812)

12. LeDoux J. 2007 The amygdala. *Curr. Biol.* **17**, R868–R874. (doi:10.1016/j.cub.2007.08.005)

13. Whalen PJ. 2007 The uncertainty of it all. *Trends Cogn. Sci.* **11**, 499. (doi:10.1016/j.tics.2007.08.016)

14. Etkin A, Klemenhagen KC, Dudman JT, Rogan MT, Hen R, Kandel ER, Hirsch J. 2004 Individual differences in trait anxiety predict the response of the basolateral amygdala to unconsciously processed fearful faces. *Neuron* **44**, 1043–1055. (doi:10.1016/j.neuron.2004.12.006)

15. Haas BW, Kazufumi K, Todd CR, Canli T. 2007 Emotional conflict and neuroticism: personality-dependent activation in the amygdala and sugenual anterior cingulate. *Behav. Neurosci.* **121**, 249–256. (doi:10.1037/0735-7044.121.2.249)

16. Stein MB, Simmons AN, Feinstein JS, Paulus MP. 2007 Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. *Am. J. Psychiat.* **164**, 318–327. (doi:10.1176/appi.ajp.164.2.318)

17. Fakra E et al. 2009 Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. *Arch. Gen. Psychiat.* **66**, 33–40. (doi:10.1001/archpsyc.66.1.33)

18. Drevets WC. 1999 Prefrontal cortical–amygdalar metabolism in major depression. *Ann. N Y Acad. Sci.* **877**, 614–637. (doi:10.1111/j.1749-6632.1999.tb09292.x)

19. Mayberg HS. 2003 Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. *Br. Med. Bull.* **65**, 193–207. (doi:10.1093/bmb/65.1.193)

20. Phillips ML, Drevets WC, Rauch SL, Lane R. 2003 Neurobiology of emotion perception. II. Implications for major psychiatric disorders. *Biol. Psychiat.* **54**, 515–528. (doi:10.1016/S0006-3223(03)00171-9)

21. Wood JN, Grafman J. 2003 Human prefrontal cortex: processing and representational perspectives. *Nat. Rev. Neurosci.* **4**, 139. (doi:10.1038/nrn1033)

22. Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN, Whalen PJ. 2011 The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. *Behav. Brain Res.* **223**, 403–410. (doi:10.1016/j.bbr.2011.04.025)

23. McEwen BS. 2007 Physiology and neurobiology of stress and adaptation: central role of the brain. *Physiol. Rev.* **87**, 873–904. (doi:10.1152/physrev.00041.2006)

24. Quirk GJ, Mueller D. 2008 Neural mechanisms of extinction learning and retrieval. *Neuropsychopharmacology* **33**, 56–72. (doi:10.1038/sj.npp.1301555)

25. Buckholtz JW et al. 2008 Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. *Mol. Psychiat.* **13**, 313–324. (doi:10.1038/sj.mp.4002020)

26. Kim MJ, Gee DG, Loucks RA, Davis FC, Whalen PJ. 2010 Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest. *Cereb. Cortex* **21**, 1667–1673. (doi:10.1093/cercor/bhq237)

27. Kim MJ, Whalen PJ. 2009 The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. *J. Neurosci.* **29**, 11 614–11 618. (doi:10.1523/JNEUROSCI.2335-09.2009)

28. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL. 2007 Recall of fear extinction in humans activates the ventromedial prefrontal cortex and

29. hippocampus in concert. *Biol. Psychiat.* **62**, 446–454. (doi:10.1016/j.biopsych.2006.10.011)

29. Pezawas L et al. 2005 5-HTTLPR polymorphism impacts human cingulate–amygdala interactions: a genetic susceptibility mechanism for depression. *Nat. Neurosci.* **8**, 828–834. (doi:10.1038/nn1463)

30. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. 2004 Extinction learning in humans: role of the amygdala and vmPFC. *Neuron* **43**, 897. (doi:10.1016/j.neuron.2004.08.042)

31. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME. 1997 Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* **386**, 824. (doi:10.1038/386824a0)

32. Sheline YI. 2003 Neuroimaging studies of mood disorder effects on the brain. *Biol. Psychiat.* **54**, 338–352. (doi:10.1016/S0006-3223(03)00347-0)

33. Sheline YI, Gado MH, Price JL. 1998 Amygdala core nuclei volumes are decreased in recurrent major depression. *Neuroreport* **9**, 2023–2028. (doi:10.1097/00001756-199806220-00021)

34. Whalen PJ, Shin LM, Somerville LH, McLean AA, Kim H. 2002 Functional neuroimaging studies of the amygdala in depression. *Semin. Clin. Neuropsychiat.* **7**, 234–242. (doi:10.1053/scnp.2002.35219)

35. Blier P, de Montigny C. 1998 Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. *Biol. Psychiat.* **44**, 313–323. (doi:10.1016/S0006-3223(98)00114-0)

36. Hariri AR, Holmes A. 2006 Genetics of emotional regulation: the role of the serotonin transporter in neural function. *Trends Cogn. Sci.* **10**, 182–191. (doi:10.1016/j.tics.2006.02.011)

37. Lucki I. 1998 The spectrum of behaviors influenced by serotonin. *Biol. Psychiat.* **44**, 151–162. (doi:10.1016/S0006-3223(98)00139-5)

38. Jacobs BL, Azmitia EC. 1992 Structure and function of the brain serotonin system. *Physiol. Rev.* **72**, 165–229.

39. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, Renner KJ. 2006 Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. *Neuroscience* **141**, 1047–1055. (doi:10.1016/j.neuroscience.2006.04.006)

40. Burghardt NS, Bush DEA, McEwen BS, LeDoux JE. 2007 Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT2C receptor antagonist. *Biol. Psychiat.* **62**, 1111–1118. (doi:10.1016/j.biopsych.2006.11.023)

41. Christianson JP, Ragole T, Amat J, Greenwood BN, Strong PV, Paul ED, Fleshner M, Watkins LR, Maier SF. 2010 5-Hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. *Biol. Psychiat.* **67**, 339–345. (doi:10.1016/j.biopsych.2009.09.011)

42. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR. 2002 Serotonin transporter genetic variation and the response of the human amygdala. *Science* **297**, 400–403. (doi:10.1126/science.1071829)

43. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, Hariri AR. 2005 A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. *Mol. Psychiat.* **10**, 884–888, 805. (doi:10.1038/sj.mp.4001725)

44. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR. 2005 A susceptibility gene for affective disorders and the response of the human amygdala. *Arch. Gen. Psychiat.* **62**, 146–152. (doi:10.1001/archpsyc.62.2.146)

45. Brown SM, Hariri AR. 2006 Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain and behavior. *Cogn. Affect. Behav. Neurosci.* **6**, 44–52. (doi:10.3758/CABN.6.1.44)

46. Munafo MR, Brown SM, Hariri AR. 2008 Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. *Biol. Psychiat.* **63**, 852–857. (doi:10.1016/j.biopsych.2007.08.016)

47. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. 2008 Escitalopram effects on insula and amygdala BOLD activation during emotional processing. *Psychopharmacology* (*Berl.*) **196**, 661–672. (doi:10.1007/s00213-007-1004-8)

48. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. 2008 Acute 5-HT reuptake blockade potentiates human amygdala reactivity. *Neuropsychopharmacology* **33**, 3221–3225. (doi:10.1038/npp.2008.52)

49. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. 2006 Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. *Biol. Psychiat.* **59**, 816–820. (doi:10.1016/j.biopsych.2005.10.015)

50. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. 2001 Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. *Biol. Psychiat.* **50**, 651–658. (doi:10.1016/S0006-3223(01)01263-X)

51. Windischberger C et al. 2010 Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. *NeuroImage* **49**, 1161–1170. (doi:10.1016/j.neuroimage.2009.10.013)

52. Fales CL, Barch DM, Rundle MM, Mintun MA, Mathews J, Snyder AZ, Sheline YI. 2009 Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. *J. Affect. Disord.* **112**, 206–211. (doi:10.1016/j.jad.2008.04.027)

53. Barnes NM, Sharp T. 1999 A review of central 5-HT receptors and their function. *Neuropharmacology* **38**, 1083–1152. (doi:10.1016/S0028-3908(99)00010-6)

54. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, el Mestikawy S, Hamon M, Descarries L. 2000 Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. *J. Comp. Neurol.* **417**, 181–194. (doi:10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A)

55. Blier P, Pineyro G, el Mansari M, Bergeron R, de Montigny C. 1998 Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. *Ann. N Y Acad. Sci.* **861**, 204–216. (doi:10.1111/j.1749-6632.1998.tb10192.x)

56. Blier P, Bergeron R. 1995 Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. *J. Clin. Psychopharmacol.* **15**, 217–222. (doi:10.1097/00004714-199506000-00011)

57. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C. 1999 PET imaging of serotonin 1A receptor binding in depression. *Biol. Psychiat.* **46**, 1375–1387. (doi:10.1016/S0006-3223(99)00189-4)

58. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang Y-Y, Van Heertum RL, Arango V, Mann JJ. 2006 Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. *Biol. Psychiat.* **59**, 106–113. (doi:10.1016/j.biopsych.2005.06.016)

59. Fisher PM, Meltzer CC, Ziolko SK, Price JC, Hariri AR. 2006 Capacity for 5-HT1A–mediated autoregulation predicts amygdala reactivity. *Nat. Neurosci.* **9**, 1362–1363. (doi:10.1038/nn1780)

60. Blakely RD, De Felice LJ, Hartzell HC. 1994 Molecular physiology of norepinephrine and serotonin transporters. *J. Exp. Biol.* **196**, 263–281.

61. Rhodes RA, Murthy NV, Dresner MA, Selvaraj S, Stavrakakis N, Babar S, Cowen PJ, Grasby PM. 2007 Human 5-HT transporter availability predicts amygdala reactivity *in vivo*. *J. Neurosci.* **27**, 9233–9237. (doi:10.1523/jneurosci.1175-07.2007)

62. Kobiella A. 2011 How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of *in vivo* serotonin transporter expression and amygdala structure. *Transl. Psychiat.* **1**, e37. (doi:10.1038/tp.2011.29)

63. Jakab RL, Goldman-Rakic PS. 1998 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. *Proc. Natl Acad. Sci. USA* **95**, 735–740. (doi:10.1073/pnas.95.2.735)

64. Miner LAH, Backstrom JR, Sanders-Bush E, Sesack SR. 2003 Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. *Neuroscience* **116**, 107–117. (doi:10.1016/S0306-4522(02)00580-8)

65. Leysen JE. 2004 5-HT2 receptors. *Curr. Drug Targets CNS Neurol. Disord.* **3**, 11–26. (doi:10.2174/1568007043482598)

66. de Almeida J, Mengod G. 2007 Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT2A receptors in human and monkey prefrontal cortex. *J. Neurochem.* **103**, 475–486. (doi:10.1111/j.1471-4159.2007.04768.x)

67. Blue ME, Yagaloff KA, Mamounas LA, Hartig PR, Molliver ME. 1988 Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex. *Brain Res.* **453**, 315–328. (doi:10.1016/0006-8993(88)90172-2)

68. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. 2006 Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with 11C.MDL 100,907. *Am. J. Psychiat.* **163**, 1580–1587. (doi:10.1176/appi.ajp.163.9.1580)

69. Frokjaer VG et al. 2008 Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. *Biol. Psychiat.* **63**, 569–576. (doi:10.1016/j.biopsych.2007.07.009)

70. Stockmeier CA. 2003 Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. *J. Psychiat. Res.* **37**, 357–373. (doi:10.1016/S0022-3956(03)00050-5)

71. Weisstaub NV et al. 2006 Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. *Science* **313**, 536–540. (doi:10.1126/science.1123432)

72. Fisher PM, Meltzer CC, Price JC, Coleman RL, Ziolko SK, Becker C, Moses-Kolko EL, Berga SL, Hariri AR. 2009 Medial prefrontal cortex 5-HT2A density is correlated with amygdala reactivity, response habituation, and functional coupling. *Cereb. Cortex* **19**, 2499–2507. (doi:10.1093/cercor/bhp022)

73. Quirk GJ, Garcia R, Gonzalez-Lima F. 2006 Prefrontal mechanisms in extinction of conditioned fear. *Biol. Psychiat.* **60**, 337–343. (doi:10.1016/j.biopsych.2006.03.010)

74. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. 1996 Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. *Neuropsychopharmacology* **14**, 35–46. (doi:10.1016/S0893-133X(96)80057-1)

75. Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F. 2004 Co-expression and *in vivo* interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. *Cereb. Cortex* **14**, 281–299. (doi:10.1093/cercor/bhg128)

76. de Almeida J, Mengod G. 2008 Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment. *J. Neurochem.* **107**, 488–496. (doi:10.1111/j.1471-4159.2008.05649.x)

77. Fisher PM, Price JC, Meltzer CC, Moses-Kolko EL, Becker C, Berga SL, Hariri AR. 2011 Medial prefrontal cortex serotonin 1A and 2A receptor binding interacts to predict threat-related amygdala reactivity. *Biol. Mood Anxiety Disord.* **1**, 2. (doi:10.1186/2045-5380-1-2)

78. Sharp T, Boothman L, Raley J, Queree P. 2007 Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. *Trends Pharmacol. Sci.* **28**, 629–636. (doi:10.1016/j.tips.2007.10.009)

79. Holmes A. 2008 Genetic variation in cortico-amygdala serotonin function and risk for

stress-related disease. *Neurosci. Biobehav. Rev.* **32**, 1293–1314. (doi:10.1016/j.neubiorev.2008.03.006)

80. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. 2001 Neurophysiological investigation of the basis of the fMRI signal. *Nature* **412**, 150–157. (doi:10.1038/35084005)

81. Fisher PM, Muñoz KE, Hariri AR. 2008 Identification of neurogenetic pathways of risk for psychopathology. *Am. J. Med. Genet. C Semin. Med Genet.* **148C**, 147–153. (doi:10.1002/ajmg.c.30173)

82. Willeit M, Praschak-Rieder N. 2010 Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. *NeuroImage* **53**, 878–892. (doi:10.1016/j.neuroimage.2010.04.030)

83. David SP, Murthy NV, Rabiner EA, Munafo MR, Johnstone EC, Jacob R, Walton RT, Grasby PM. 2005 A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. *J. Neurosci.* **25**, 2586–2590. (doi:10.1523/JNEUROSCI.3769-04.2005)

84. Aznavour N, Rbah L, Riad M, Reilhac A, Costes N, Descarries L, Zimmer L. 2006 A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. *NeuroImage* **33**, 834–842. (doi:10.1016/j.neuroimage.2006.08.012)

85. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. 2010 Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. *J. Cereb. Blood Flow Metab.* **30**, 1682–1706. (doi:10.1038/jcbfm.2010.104)

86. Licht CL, Marcussen AB, Wegener G, Overstreet DH, Aznar S, Knudsen GM. 2009 The brain 5-HT4 receptor binding is down-regulated in the flinders sensitive line depression model and in response to paroxetine administration. *J. Neurochem.* **109**, 1363–1374. (doi:10.1111/j.1471-4159.2009.06050.x)

87. Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, Farde L. 2010 Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain. *Synapse* **64**, 573–577. (doi:10.1002/syn.20780)

88. Milak MS, DeLorenzo C, Zanderigo F, Prabhakaran J, Kumar JSD, Majo VJ, Mann JJ, Parsey RV. 2010 *In vivo* quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. *J. Nucl. Med.* **51**, 1892–1900. (doi:10.2967/jnumed.110.076257)